Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Urology Reports
Erschienen in: Current Urology Reports 6/2011

01.12.2011 | Overactive Bladder (Gopal Badlani, Section Editor)

Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management

verfasst von: Arun Sahai, Eduardo Cortes, Jai Seth, Muhammad Shamim Khan, Jalesh Panicker, Cornelius Kelleher, Thomas M. Kessler, Clare J. Fowler, Prokar Dasgupta

Erschienen in: Current Urology Reports | Ausgabe 6/2011

Einloggen, um Zugang zu erhalten

Abstract

Lower urinary tract dysfunction can have a significant impact on patients with spinal cord injury. Over the years, many treatment options have become available. This article reviews the assessment and management of neurogenic detrusor overactivity, with a particular focus on articles from the recent literature. Recent guidelines on the subject will be discussed. Management options include antimuscarinics and bladder emptying measures, botulinum toxin A, and neuromodulation in refractory cases and surgery for intractable cases. Recent and relevant publications in these areas will be summarized and discussed.
Literatur
1.
Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn. 2006;25(5):441–5.PubMedCrossRef
2.
DeVivo MJ, Chen Y, Mennemeyer ST, Deutsch A. Topics in Spinal Cord Injury Rehabilitation. 2011;16(4):1–9.CrossRef
3.
Yue Cao YC, Michael J. DeVivo. Topics in Spinal Cord Injury Rehabilitation. 2011;16(4):10–6.
4.
Hackler RH. A 25-year prospective mortality study in the spinal cord injured patient: comparison with the long-term living paraplegic. J Urol. 1977;117(4):486–8.PubMed
5.
Lidal IB, Snekkevik H, Aamodt G, Hjeltnes N, Biering-Sorensen F, Stanghelle JK. Mortality after spinal cord injury in Norway. J Rehabil Med. 2007;39(2):145–51.PubMedCrossRef
6.
• Abrams P, Agarwal M, Drake M, El-Masri W, Fulford S, Reid S, et al. A proposed guideline for the urological management of patients with spinal cord injury. BJU Int. 2008 Apr;101(8):989–94. This guideline was developed by doctors in the United Kingdom, experts in the urinary tract management of patients with spinal cord injury. PubMedCrossRef
7.
• J. Pannek MS, B. Blok, D. Castro-Diaz, G. Del Popolo, G. Kramer, P. Radziszewski, A. Reitz, J-J. Wyndaele. Guidelines on neurogenic lower urinary tract dysfunction. European Association of Urology. 2011. These are current guidelines on the management of various types of neurogenic lower urinary tract dysfunction.
8.
de Groat WC, Yoshimura N. Mechanisms underlying the recovery of lower urinary tract function following spinal cord injury. Prog Brain Res. 2006;152:59–84.PubMedCrossRef
9.
•• de Groat WC, Yoshimura N. Plasticity in reflex pathways to the lower urinary tract following spinal cord injury. Exp Neurol. May 9. This is an excellent recent review from leaders in their field regarding the neurophysiology of micturition and changes that occur following spinal cord injury.
10.
Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–66.PubMedCrossRef
11.
Wing PC. Early acute management in adults with spinal cord injury: a clinical practice guideline for health-care providers. Who should read it? J Spinal Cord Med. 2008;31(4):360.PubMed
12.
Watanabe T, Rivas DA, Chancellor MB. Urodynamics of spinal cord injury. Urol Clin North Am. 1996;23(3):459–73.PubMedCrossRef
13.
Kaplan SA, Chancellor MB, Blaivas JG. Bladder and sphincter behavior in patients with spinal cord lesions. J Urol. 1991;146(1):113–7.PubMed
14.
McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. 1981. J Urol. 2002;167(2 Pt 2):1049–53. discussion 54.PubMedCrossRef
15.
Burns AS, Rivas DA, Ditunno JF. The management of neurogenic bladder and sexual dysfunction after spinal cord injury. Spine (Phila Pa 1976). 2001;26(24 Suppl):129–36.CrossRef
16.
Wyndaele JJ, Madersbacher H, Kovindha A. Conservative treatment of the neuropathic bladder in spinal cord injured patients. Spinal Cord. 2001;39(6):294–300.PubMedCrossRef
17.
Hansen RB, Biering-Sorensen F, Kristensen JK. Urinary incontinence in spinal cord injured individuals 10–45 years after injury. Spinal Cord. 2010;48(1):27–33.PubMedCrossRef
18.
Hansen RB, Biering-Sorensen F, Kristensen JK. Bladder emptying over a period of 10–45 years after a traumatic spinal cord injury. Spinal Cord. 2004;42(11):631–7.PubMedCrossRef
19.
Bennett CJ, Young MN, Adkins RH, Diaz F. Comparison of bladder management complication outcomes in female spinal cord injury patients. J Urol. 1995;153(5):1458–60.PubMedCrossRef
20.
Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. Bladder management after spinal cord injury in the United States 1972 to 2005. J Urol. 2010;184(1):213–7.PubMedCrossRef
21.
Pettersson-Hammerstad K, Jonsson O, Svennung IB, Karlsson AK. Impaired renal function in newly spinal cord injured patients improves in the chronic state–effect of clean intermittent catheterization? J Urol. 2008;180(1):187–91. discussion 91.PubMedCrossRef
22.
Vaidyanathan S, Soni BM, Singh G, Oo T, Hughes PL. Barriers to implementing intermittent catheterisation in spinal cord injury patients in Northwest Regional Spinal Injuries Centre, Southport, U.K. ScientificWorldJournal. 2011;11:77–85.PubMedCrossRef
23.
Cameron AP, Wallner LP, Forchheimer MB, Clemens JQ, Dunn RL, Rodriguez G, et al. Medical and psychosocial complications associated with method of bladder management after traumatic spinal cord injury. Arch Phys Med Rehabil. 2011;92(3):449–56.PubMedCrossRef
24.
Liu CW, Attar KH, Gall A, Shah J, Craggs M. The relationship between bladder management and health-related quality of life in patients with spinal cord injury in the UK. Spinal Cord. 2009;48(4):319–24.PubMedCrossRef
25.
Saint S, Elmore JG, Sullivan SD, Emerson SS, Koepsell TD. The efficacy of silver alloy-coated urinary catheters in preventing urinary tract infection: a meta-analysis. Am J Med. 1998;105(3):236–41.PubMedCrossRef
26.
Desai DG, Liao KS, Cevallos ME, Trautner BW. Silver or nitrofurazone impregnation of urinary catheters has a minimal effect on uropathogen adherence. J Urol. 2010;184(6):2565–71.
27.
Cardenas DD, Moore KN, Dannels-McClure A, Scelza WM, Graves DE, Brooks M, et al. Intermittent catheterization with a hydrophilic-coated catheter delays urinary tract infections in acute spinal cord injury: a prospective, randomized, multicenter trial. PM R. 2011 May;3(5):408–17.
28.
Jahn P, Preuss M, Kernig A, Seifert-Huhmer A, Langer G. Types of indwelling urinary catheters for long-term bladder drainage in adults. Cochrane Database Syst Rev. 2007(3):CD004997.
29.
Ryu KH, Kim YB, Yang SO, Lee JK, Jung TY. Results of urine culture and antimicrobial sensitivity tests according to the voiding method over 10 years in patients with spinal cord injury. Korean J Urol. 2011;52(5):345–9.
30.
Everaert K, Lumen N, Kerckhaert W, Willaert P, van Driel M. Urinary tract infections in spinal cord injury: prevention and treatment guidelines. Acta Clin Belg. 2009;64(4):335–40.PubMed
31.
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol. 2008;54(3):543–62.PubMedCrossRef
32.
Bennett N, O’Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol. 2004;171(2 Pt 1):749–51.PubMedCrossRef
33.
O’Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med. 2003;26(2):159–62.PubMed
34.
• Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol. 2008 May;53(5):1021–8. This was a small study assessing combined antimuscarinic therapy in those who failed dose escalation with monotherapy. This approach resulted in successful treatment for 85% of patients. PubMedCrossRef
35.
Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology. 2009;74(4):741–5.PubMedCrossRef
36.
Natalin R, Reis LO, Alpendre C, Ikari LY, Prudente A, D’Ancona CA. Triple therapy in refractory detrusor overactivity: a preliminary study. World J Urol. 2010;28(1):79–85.
37.
Apostolidis A, Dasgupta P, Denys P, Elneil S, Fowler CJ, Giannantoni A, et al. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur Urol. 2009;55(1):100–19.PubMedCrossRef
38.
Ehren I, Volz D, Farrelly E, Berglund L, Brundin L, Hultling C, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol. 2007;41(4):335–40.PubMedCrossRef
39.
• Schurch B, de Seze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200. This article provides evidence for the efficacy of botulinum toxin A in treating NDO from a phase 2 placebo-controlled randomized trial. PubMedCrossRef
40.
Cruz F, Heesakkers J, Aliotta P, Thompson C, Lam W, Daniell G, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. European Urology Supplements. 2011;10(2):190.CrossRef
41.
Mascarenhas F, Cocuzza M, Gomes CM, Leao N. Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients. Neurourol Urodyn. 2008;27(4):311–4.PubMedCrossRef
42.
Del Popolo G, Filocamo MT, Li Marzi V, Macchiarella A, Cecconi F, Lombardi G, et al. Neurogenic detrusor overactivity treated with english botulinum toxin a: 8-year experience of one single centre. Eur Urol. 2008;53(5):1013–19.PubMedCrossRef
43.
• Dowson C, Khan MS, Dasgupta P, Sahai A. Repeat botulinum toxin-A injections for treatment of adult detrusor overactivity. Nat Rev Urol. 2010 Dec;7(12):661–7. This review summarizes the efficacy and safety of repeated botulinum toxin injections for NDO. PubMedCrossRef
44.
Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.PubMedCrossRef
45.
Kessler TM, Khan S, Panicker J, Roosen A, Elneil S, Fowler CJ. Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life. Obstet Gynecol. 2009;113(5):1046–51.PubMed
46.
Wefer B, Ehlken B, Bremer J, Burgdorfer H, Domurath B, Hampel C, et al. Treatment outcomes and resource use of patients with neurogenic detrusor overactivity receiving botulinum toxin A (BOTOX) therapy in Germany. World J Urol. 2010;28(3):385–90.PubMedCrossRef
47.
Hori S, Patki P, Attar KH, Ismail S, Vasconcelos JC, Shah PJ. Patients’ perspective of botulinum toxin-A as a long-term treatment option for neurogenic detrusor overactivity secondary to spinal cord injury. BJU Int. 2009;104(2):216–20.PubMedCrossRef
48.
Vastenholt JM, Snoek GJ, Buschman HP, van der Aa HE, Alleman ER, Ijzerman MJ. A 7-year follow-up of sacral anterior root stimulation for bladder control in patients with a spinal cord injury: quality of life and users’ experiences. Spinal Cord. 2003;41(7):397–402.PubMedCrossRef
49.
Van Kerrebroeck PE, Koldewijn EL, Rosier PF, Wijkstra H, Debruyne FM. Results of the treatment of neurogenic bladder dysfunction in spinal cord injury by sacral posterior root rhizotomy and anterior sacral root stimulation. J Urol. 1996;155(4):1378–81.PubMedCrossRef
50.
Kutzenberger J, Domurath B, Sauerwein D. Spastic bladder and spinal cord injury: seventeen years of experience with sacral deafferentation and implantation of an anterior root stimulator. Artif Organs. 2005;29(3):239–41.PubMedCrossRef
51.
Hohenfellner M, Pannek J, Botel U, Dahms S, Pfitzenmaier J, Fichtner J, et al. Sacral bladder denervation for treatment of detrusor hyperreflexia and autonomic dysreflexia. Urology. 2001;58(1):28–32.PubMedCrossRef
52.
• Martens FM, den Hollander PP, Snoek GJ, Koldewijn EL, van Kerrebroeck PE, Heesakkers JP. Quality of life in complete spinal cord injury patients with a Brindley bladder stimulator compared to a matched control group. Neurourol Urodyn. 2011 Apr;30(4):551–5. This cross-sectional study assessed QoL in patients using SARS compared to a matched controlled group. PubMedCrossRef
53.
• Kessler TM, La Framboise D, Trelle S, Fowler CJ, Kiss G, Pannek J, et al. Sacral neuromodulation for neurogenic lower urinary tract dysfunction: systematic review and meta-analysis. Eur Urol. 2010;58(6):865–74. This is a systematic review and meta-analysis of the efficacy and safety of neuromodulation for neurogenic lower urinary tract dysfunction, with a nice summary on potential mechanisms of action.
54.
•• Sievert KD, Amend B, Gakis G, Toomey P, Badke A, Kaps HP, et al. Early sacral neuromodulation prevents urinary incontinence after complete spinal cord injury. Ann Neurol. 2010 Jan;67(1):74–84. This is a landmark study assessing the use of early neuromodulation during the AD phase of SCI. Results suggest that NDO and DSD can be prevented with this strategy. PubMedCrossRef
55.
Game XKT, Elneil S, Hamid R. Neurogenic bladder dysfunction: surgical interventional approaches. Pelvic Organ Dysfunction in Neurological Disease: Cambridge Medicine; 2010, p. 112–26.
56.
Cartwright PC, Snow BW. Bladder autoaugmentation: early clinical experience. J Urol. 1989;142(2 Pt 2):505–8. discussion 20–1.PubMed
57.
Stohrer M, Kramer G, Goepel M, Lochner-Ernst D, Kruse D, Rubben H. Bladder autoaugmentation in adult patients with neurogenic voiding dysfunction. Spinal Cord. 1997;35(7):456–62.PubMedCrossRef
58.
Leng WW, Blalock HJ, Fredriksson WH, English SF, McGuire EJ. Enterocystoplasty or detrusor myectomy? Comparison of indications and outcomes for bladder augmentation. J Urol. 1999;161(3):758–63.PubMedCrossRef
59.
60.
Chen JL, Kuo HC. Long-term outcomes of augmentation enterocystoplasty with an ileal segment in patients with spinal cord injury. J Formos Med Assoc. 2009;108(6):475–80.PubMedCrossRef
61.
Gerharz EW, Mansson A, Hunt S, Skinner EC, Mansson W. Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol. 2005;174(5):1729–36.PubMedCrossRef
62.
Fazili T, Bhat TR, Masood S, Palmer JH, Mufti GR. Fate of the leftover bladder after supravesical urinary diversion for benign disease. J Urol. 2006;176(2):620–1.PubMedCrossRef
63.
Cheng JN, Lawrentschuk N, Gyomber D, Rogerson J, Bolton DM. Cystectomy in patients with spinal cord injury: indications and long-term outcomes. J Urol. 2010;184(1):92–8.PubMedCrossRef
Metadaten
Titel
Neurogenic Detrusor Overactivity in Patients With Spinal Cord Injury: Evaluation and Management
verfasst von
Arun Sahai
Eduardo Cortes
Jai Seth
Muhammad Shamim Khan
Jalesh Panicker
Cornelius Kelleher
Thomas M. Kessler
Clare J. Fowler
Prokar Dasgupta
Publikationsdatum
01.12.2011
Verlag
Current Science Inc.
Erschienen in
Current Urology Reports / Ausgabe 6/2011
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI
https://doi.org/10.1007/s11934-011-0221-1

Weitere Artikel der Ausgabe 6/2011

Current Urology Reports 6/2011 Zur Ausgabe

Overactive Bladder (Gopal Badlani, Section Editor)

Updates in the Management of the Overactive Bladder in Patients with Myelomeningocele

ReviewPaper

Penile Fracture and Penile Reconstruction

Clinical Trial Report

The Scientific Rationale for Using Biomaterials in Stress Urinary Incontinence and Pelvic Organ Prolapse

Erectile Dysfunction (Thomas Lue, Section Editor)

Rise of Herbal and Traditional Medicine in Erectile Dysfunction Management

Overactive Bladder (Gopal Badlani, Section Editor)

Bladder Dysfunction in Patients with Diabetes

ReviewPaper

Androgens are Fundamental in the Maintenance of Male Sexual Health

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise